These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 38259484)
1. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD. Wang L; Xia R; Li X; Shan J; Wang S Front Immunol; 2023; 14():1293100. PubMed ID: 38259484 [TBL] [Abstract][Full Text] [Related]
2. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD. Lin L; Wu Y; Hang H; Lu J; Ding Y Front Immunol; 2022; 13():853891. PubMed ID: 35898513 [TBL] [Abstract][Full Text] [Related]
3. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults. Duan Z; Feng J J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419 [TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369 [TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369 [TBL] [Abstract][Full Text] [Related]
6. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD. Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103 [TBL] [Abstract][Full Text] [Related]
7. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025 [TBL] [Abstract][Full Text] [Related]
8. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder. Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ Front Immunol; 2024; 15():1320094. PubMed ID: 38576611 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Wang M; Xia D; Sun L; Bi J; Xie K; Wang P Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033 [TBL] [Abstract][Full Text] [Related]
11. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V; Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777 [TBL] [Abstract][Full Text] [Related]
12. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C Front Immunol; 2021; 12():647618. PubMed ID: 33796113 [No Abstract] [Full Text] [Related]
14. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder. Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817 [TBL] [Abstract][Full Text] [Related]
18. Clinical use of CSF neopterin levels in CNS demyelinating diseases. Miyaue N; Hosokawa Y; Yamanishi Y; Tada S; Ando R; Nagai M J Neurol Sci; 2022 Oct; 441():120385. PubMed ID: 36027640 [TBL] [Abstract][Full Text] [Related]
19. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease. Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094 [TBL] [Abstract][Full Text] [Related]
20. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS. Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]